Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.
Eklund
Kari K
KK
Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland. kari.eklund@HUS.fi
Lindstedt
Ken
K
Sandler
Charlotta
C
Kovanen
Petri T
PT
Laasonen
Leena
L
Juurikivi
Annika
A
Wolff
Henrik
H
Mykkänen
Marko
M
Joensuu
Heikki
H
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010147:Pain Measurement; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate